文献速递淋巴瘤

靶向测序综合遗传分析识别套细胞淋巴瘤危险因素并预测患者结局:来自EU-MCL网络试验的结果

Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.
PubMed 文献 · Leukemia · 2024-09-16

研究对欧洲套细胞淋巴瘤(MCL)网络试验中180例患者的外周血DNA进行EuroClonality(EC)-NDC靶向测序,94%检出IGH::CCND1融合,79%存在至少1个体细胞基因突变,83%检出拷贝数变异(CNV)。TP53mut、NOTCH1mut、FAT1mut、TRAF2del、CDKN2A/Bdel和MAP2K1amp与较差的无失败生存(FFS)和总生存(OS)相关;遗传复杂(≥3个CNV)见于51%的分析患者,与FFS和OS受损显著相关。作者结论认为外周血和骨髓靶向测序可可靠检测MCL诊断和预后相关遗传因素,便于临床常规开展遗传学分析。

要点

  • 180例MCL患者中94%检出IGH::CCND1融合,79%有至少1个体细胞基因突变。
  • TP53mut、NOTCH1mut、FAT1mut、TRAF2del、CDKN2A/Bdel和MAP2K1amp与较差FFS和OS相关。
  • 遗传复杂(≥3个CNV)见于51%的分析患者,与FFS和OS受损显著相关。

核心结论

  • 外周血和骨髓靶向测序可可靠检测MCL诊断和预后相关遗传因素,便于临床常规开展遗传学分析。

研究设计与样本

  • 对欧洲MCL网络试验中180例患者的外周血DNA进行EuroClonality(EC)-NDC靶向测序,行全面基因组特征分析。

主要发现

  • 94%患者检出IGH::CCND1融合,全部患者检出克隆性IGH-V-(D)-J重排,79%有至少1个体细胞基因突变。
  • 突变最多的基因为ATM、TP53、KMT2D、SAMHD1、BIRC3和NFKBIE。
  • 83%患者检出CNV,最常缺失的基因为RB1、ATM、CDKN2A/B和TP53,最常扩增的基因为KLF2、CXCR4、CCND1、MAP2K1和MYC。
  • CNV和突变在老年患者中更常见,且对预后有不良影响。
  • TP53mut、NOTCH1mut、FAT1mut、TRAF2del、CDKN2A/Bdel和MAP2K1amp与较差FFS和OS相关,TRAF2mut、EGR2del和BCL2amp仅与较差OS相关;遗传复杂(≥3个CNV)见于51%的分析患者,与FFS和OS受损显著相关。

关键数值与推荐

  • CNV检出率83%,遗传复杂(≥3个CNV)见于51%的分析患者。

临床怎么用

  • 作者结论认为外周血和骨髓靶向测序可可靠检测MCL诊断和预后相关遗传因素,便于临床常规开展遗传学分析。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent studies highlighted genetic aberrations associated with prognosis in Mantle Cell lymphoma (MCL), yet comprehensive testing is not implemented in clinical routine. We conducted a comprehensive genomic characterization of 180 patients from the European MCL network trials by targeted sequencing of peripheral blood DNA using the EuroClonality(EC)-NDC assay. The IGH::CCND1 fusion was identified in 94% of patients, clonal IGH-V-(D)-J rearrangements in all, and 79% had ≥1 somatic gene mutation. The top mutated genes were ATM, TP53, KMT2D, SAMHD1, BIRC3 and NFKBIE. Copy number variations (CNVs) were detected in 83% of patients with RB1, ATM, CDKN2A/B and TP53 being the most frequently deleted and KLF2, CXCR4, CCND1, MAP2K1 and MYC the top amplified genes. CNVs and mutations were more frequently observed in older patients with adverse impact on prognosis. TP53mut, NOTCH1mut, FAT1mut TRAF2del, CDKN2A/Bdel and MAP2K1amp were linked to inferior failure-free (FFS) and overall survival (OS), while TRAF2mut, EGR2del and BCL2amp related to inferior OS only. Genetic complexity (≥3 CNVs) observed in 51% of analysed patients was significantly associated with impaired FFS and OS. We demonstrate that targeted sequencing from peripheral blood and bone marrow reliably detects diagnostically and prognostically important genetic factors in MCL patients, facilitating genetic characterization in clinical routine.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Khouja M, Jiang L, Pal K, et al. Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials. Leukemia. 2024. PMID: 39284897. doi:10.1038/s41375-024-02375-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。